Neurochemical effects of oxytocin in people at clinical high risk for psychosis
Cathy Davies,Grazia Rutigliano,Andrea De Micheli,James M Stone,Valentina Ramella-Cravaro,Umberto Provenzani,Marco Cappucciati,Eleanor Scutt,Yannis Paloyelis,Dominic Oliver,Silvia Murguia,Fernando Zelaya,Paul Allen,Sukhi Shergill,Paul Morrison,Steve Williams,David Taylor,David J Lythgoe,Philip McGuire,Paolo Fusar-Poli
DOI: https://doi.org/10.1016/j.euroneuro.2019.03.008
Abstract:Alterations in neurochemical metabolites are thought to play a role in the pathophysiology of psychosis onset. Oxytocin, a neuropeptide with prosocial and anxiolytic properties, modulates glutamate neurotransmission in preclinical models but its neurochemical effects in people at high risk for psychosis are unknown. We used proton magnetic resonance spectroscopy (1H-MRS) to examine the effects of intranasal oxytocin on glutamate and other metabolites in people at Clinical High Risk for Psychosis (CHR-P) in a double-blind, placebo-controlled, crossover design. 30 CHR-P males were studied on two occasions, once after 40IU intranasal oxytocin and once after placebo. The effects of oxytocin on the concentration of glutamate, glutamate+glutamine and other metabolites (choline, N-acetylaspartate, myo-inositol) scaled to creatine were examined in the left thalamus, anterior cingulate cortex (ACC) and left hippocampus, starting approximately 75, 84 and 93 min post-dosing, respectively. Relative to placebo, administration of oxytocin was associated with an increase in choline levels in the ACC (p=.008, Cohen's d = 0.54). There were no other significant effects on metabolite concentrations (all p>.05). Our findings suggest that, at ∼75-99 min post-dosing, a single dose of intranasal oxytocin does not alter levels of neurochemical metabolites in the thalamus, ACC, or hippocampus in those at CHR-P, aside from potential effects on choline in the ACC.